文献速递临床试验与 GCP流行病学与生物统计

评估获批SARS-CoV-2疫苗在免疫抑制患者中的试验平台:比较两种mRNA疫苗的试点试验首个子方案

A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
PubMed 文献 · Trials · 2021-10-21

该研究计划建立一个嵌套于瑞士HIV队列研究和瑞士移植队列研究的试验平台,并开展一项多中心、随机、开放标签、两臂的试点子试验,比较Comirnaty®与COVID-19 mRNA Vaccine Moderna®在免疫抑制患者中的免疫原性。主要临床结局是接种后3个月对比基线的pan-Ig抗体应答变化,同时评估试验平台可行性。假设两组疫苗反应性均为90%,采用非劣效性设计,需样本量380例(每组190例)以达到90%统计功效和0.025的I类错误率。

要点

  • 在免疫抑制患者中比较两种mRNA疫苗的随机对照试点试验。
  • 主要结局为接种后3个月pan-Ig抗体应答相对基线的变化。
  • 样本量380例,非劣效界值为参考组差值95%CI上限不超过10%。

核心结论

  • 该试点试验将评估两种mRNA疫苗在HIV感染者和器官移植受者中的免疫原性,并为瑞士进一步开展平台试验奠定基础。

研究设计与样本

  • 多中心、随机对照、开放标签、两臂的试点子试验,嵌套于瑞士HIV队列研究和瑞士移植队列研究。
  • 计划纳入380例受试者,每组190例,随机分配至Comirnaty®组或COVID-19 mRNA Vaccine Moderna®组。

关键数值与推荐

  • 主要临床结局为pan-Ig抗S1-RBD抗体应答变化(基线 vs 首次接种后3个月),以≥0.8 units/ml为阳性应答。
  • 假设两组疫苗反应性均为90%,采用非劣效性设计,要求参考组差值95%双侧置信区间上限不超过10%。
  • 样本量380例(每组190例)可达到90%统计功效和0.025的I类错误率。

临床怎么用

  • 该试验平台利用常规收集的队列数据,可快速评估干预措施在免疫抑制人群中的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Late 2019, a new highly contagious coronavirus SARS-CoV-2 has emerged in Wuhan, China, causing within 2 months a pandemic with the highest disease burden in elderly and people with pre-existing medical conditions. The pandemic has highlighted that new and more flexible clinical trial approaches, such as trial platforms, are needed to assess the efficacy and safety of interventions in a timely manner. The two existing Swiss cohorts of immunocompromised patients (i.e., Swiss HIV Cohort Study (SHCS) and Swiss Transplant Cohort Study (STCS)) are an ideal foundation to set-up a trial platform in Switzerland leveraging routinely collected data. Within a newly founded trial platform, we plan to assess the efficacy of the first two mRNA SARS-CoV-2 vaccines that reached market authorization in Switzerland in the frame of a pilot randomized controlled trial (RCT) while at the same time assessing the functionality of the trial platform. METHODS: We will conduct a multicenter randomized controlled, open-label, 2-arm sub-study pilot trial of a platform trial nested into two Swiss cohorts. Patients included in the SHCS or the STCS will be eligible for randomization to either receiving the mRNA vaccine Comirnaty® (Pfizer/BioNTech) or the COVID-19 mRNA Vaccine Moderna®. The primary clinical outcome will be change in pan-lg antibody response (pan-Ig anti-S1-RBD; baseline vs. 3 months after first vaccination; binary outcome, considering ≥ 0.8 units/ml as a positive antibody response). The pilot study will also enable us to assess endpoints related to trial conduct feasibility (i.e., duration of RCT set-up; time of patient recruitment; patient consent rate; proportion of missing data). Assuming vaccine reactivity of 90% in both vaccine groups, we power our trial, using a non-inferiority margin such that a 95% two-sided confidence interval excludes a difference in favor of the reference group of more than 10%. A sample size of 380 (190 in each treatment arm) is required for a statistical power of 90% and a type I error of 0.025. The study is funded by the Swiss National Science Foundation (National Research Program NRP 78, "COVID-19"). DISCUSSION: This study will provide crucial information about the efficacy and safety of the mRNA SARS-CoV-2 vaccines in HIV patients and organ transplant recipients. Furthermore, this project has the potential to pave the way for further platform trials in Switzerland. TRIAL REGISTRATION: ClinicalTrials.gov NCT04805125 . Registered on March 18, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Speich B, Chammartin F, Smith D, et al. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. Trials. 2021. PMID: 34674742. doi:10.1186/s13063-021-05664-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。